«

»

Jun 21

A held biopharmaceutical company privately.

McGuire Dawn, Chief Medical Officer of Acologix. ‘The previously demonstrated capability of AC-100 to promote regeneration of underlying broken bone makes the use of AC-100 a distinctive approach for repair and regeneration of hard cells in OA, RA, and traumatic injury.’.. Acologix presents preclinical research results of AC-100 on cartilage regeneration at ORS annual meeting Acologix, Inc., a held biopharmaceutical company privately, announced the outcomes of its most recent preclinical study demonstrating that AC-100 today, its therapeutic product candidate produced from an endogenous human protein, promotes cartilage regeneration in a big animal model.Menopausal symptoms such as hot flashes, fatigue, sweating, insomnia, and arthralgia were common among all the women in the study but were predictably somewhat more common in those acquiring exemestane. Also of potential clinical importance, more women in the exemestane group self-reported that menopause-related vasomotor and sexual symptoms had worsened. However, these symptoms did not appear to affect self-reports of overall health-related QOL among those taking exemestane because summary steps of physical and mental the different parts of the SF-36 didn’t differ between the two study groups.